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a b s t r a c t
Heart failure (HF) is a major public health problem and the approach for an accurate individualization
of HF risk and care should include a profile of laboratory data, in addition to clinical and imaging data.
The possibility of identifying the most vulnerable patients is clinically important, especially considering
that many therapeutic interventions are available today. This goal has not been yet reached although
many novel biomarkers have been proposed and tested. The complexity of the biochemical network at
the basis of HF pathophysiology clearly suggests that a single marker cannot reflect all the features of
this syndrome, whereas the combined use of more indices would better characterize HF patients and
create new options for their management, helping identify which patients to follow more closely. The
multimarker approach, considering various biochemical pathways simultaneously, bases its robustness
on a suitable choice of indices known to be individually associated with HF. The choice of biomarker
combination is essential to the performance of the multimarker strategy. A major problem in selecting
the biomarker profile is the proportional increase in economic burden; thus a “parsimonious” biomarker
combination has to be used in a cost-effective evaluation. Statistical analysis and analytical performance
of the different elements of the combination, in turn, may heavily influence results.
This review summarizes the results obtained using a multimarker approach for HF risk stratification,
for predicting HF incidence in a population, and evaluating the response to therapy. An insight into tran-
scriptomic biomarkers, recently proposed for HF individual risk assessment, is also reported. A reliable
selection of biomarkers for the careful management of HF patients is of pivotal importance in reducing
healthcare costs without reducing patient care.
© 2011 Elsevier Ltd. All rights reserved.
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1. Introduction
1.1. The long way of the heart failure biomarkers
Knowledge of the molecular mechanisms at the basis of var-
ious diseases plays an important role in biomedical fields such
as molecular medicine, thanks to the possibility of finding new
biomarkers that can univocally recognize specific disease path-
ways [1]. As to heart failure (HF), the proposal of new biomarkers
follows our understanding of molecular pathways at the basis of
this complex disease. The first proposed biomarkers were neuro-
hormones such as catecholamines, in particular norepinephrine. In
1962, elevated levels of norepinephrine in HF patients and their
further increase after physical exercise was described, and an acti-
vation and a pathogenetic role of the sympathetic nervous system
in HF was demonstrated [2]. In 1984, an association between nore-
pinephrine and mortality in HF patients was found [3]. In 1990,
the renin–angiotensin–aldosterone system was also shown to be
activated in HF [4]. Immediately after its identification, attention
was focused on endothelin (ET)-1, a 21 amino acid peptide released
by vascular endothelium with potent vasoconstrictive action [5].
Besides inducing fibrosis of ventricles and vasculature, endothelin
is apotentmodulatorof the releaseof otherneuro-hormones, natri-
uretic peptides included [6]. Natriuretic peptides have a central
role in biohumoral characterization of HF, primarily brain natri-
uretic peptide (BNP), and N-terminal pro-BNP (NT-proBNP), that
are indices of myocyte stress, being released during hemodynamic
stress [6]. More recently, the C-type natriuretic peptide (CNP) also
resulted to be involved in HF pathophysiology [7]; its circulating
levels increase as a function of HF severity [8] and cardiac produc-
tion during HF was shown [9,10]. As to inflammation, in the 1990s
a role for Interleukin (IL)-6 and Tumor Necrosis Factor (TNF)was
recognized [11], although attention was focused on inflammation
in the pathogenesis and progression of HF long before in 1954,with
studies on C reactive protein (CRP) [12]. Very recently, among the
novel biomarkers ofHF, pentraxin (PTX)-3, an early indexof inflam-
mation belonging to the CRP family [13], has been proposed for risk
stratification [14]. High circulating levels of PTX-3 are also con-
sidered a signal of myocyte damage, as observed in patients with
acutemyocardial injury [15]. Evaluation of the presence ofmyocyte
injury attracts increasing attention as a factor influencing the HF
progression. Cardiac troponins (cTn), sensitive and specific indices
of acute myocardial injury, are used to reveal myocyte injury fol-
lowing myocardial stress due to inflammation, oxidative processes
andneuro-hormonal activation [16]. Increased cTnI levels, an index
of myofibril damage, has been demonstrated to be an independent
predictor ofmortality inHF [17,18];more recently, othermolecules
such as Heart-type Fatty Acid Binding Protein (H-FABP), a marker
of cellular membrane damage, resulted relevant in the risk stratifi-
cation of HF patients [19]. Elevated levels of both cTnT and H-FABP,
markersof twodifferentkindsofmyocytedamage, are independent
predictors of adverse outcome in HF subjects [20].
Table 1 summarizes the main classes of biological molecules to
be used as possible biomarkers in HF syndrome. As suggested by
Braunwald andBristow [21] early in the twentieth century, increas-
ingknowledgeof themechanisms leading to the cardiac failure and,
Table 1
Biomarker classes for heart failure.
Biomarker Suggested clinical applications
Neurohormones
Catecholamines Prognosis
Renin–angiotensin–aldosterone
system (RAAS)
Prognosis
Natriuretic peptides (ANP, BNP,
NT-proBNP, MR-proANP and other
related peptides)
Diagnosis, prognosis, risk
stratification, therapy monitoring
Arginine vasopressin and copeptin Prognosis
Endothelin Prognosis, therapeutic target
Chromogranin A and B Diagnosis
Adrenomedullin Prognosis
Myocyte injury
Cardiac troponins (cTnI and cTnT) Diagnosis, prognosis, risk
stratification
Heart-type fatty acid binding protein
(H-FABP)
Diagnosis, prognosis, risk
stratification
Myosin light-chain kinase I Prognosis
Fas (APO-1) Prognosis
Pentraxin (PTX)3 Prognosis, risk stratification
Inflammation
C-reactive protein Prognosis, risk stratification
Cytokines and related receptors
(IL-1, IL-2, IL-6, IL-8, IL-18, TNF,
growth differentiation factor 15, ST2)
Prognosis, risk stratification
PTX3 Prognosis, risk stratification
Adipokines (adiponectin, leptin,
resistin, ghrelin)
Prediction of HF incidence,
prognosis, risk stratification
Procalcitonin Prognosis
Neopterin Prognosis
Osteoprotegerin Prognosis, risk stratification
Oxidative stress
Oxidized low-density lipoproteins Prognosis
Myeloperoxidase (MPO) Prognosis
Urinary piopyrrins Prognosis
Urinary and plasma isoprostanes Prognosis
Plasma malondialdehyde Diagnosis
Gamma-glutamyl transferases (GGT) Prognosis
Uric acid Prognosis
Matrix and cellular remodelling
Matrix metalloproteinases (MMPs)
and MPP tissue inhibitors (TIMPs)
Prognosis, risk stratification, aid in
elucidating the HF pathogenesis
Collagen propeptides Prognosis
Propeptide procollagen type I and III Prognosis
Osteopontin (OPN) (and other
matricellular proteins)
Prognosis, aid in elucidating the HF
pathogenesis
Galectin-3 Prognosis, risk stratification
Endothelial dysfunction
Adhesion molecules (ICAM,
selectin-P)
Prognosis
Endothelin Prognosis, therapeutic target
Adiponectin Prediction of HF incidence,
prognosis, risk stratification
Homocysteine Prediction of HF incidence
C-type natriuretic peptide (CNP) Diagnosis, prognosis, aid in
elucidating the HF pathogenesis
Other markers (organ failure, cachexia, comorbidity)
Triiodothyronine Prognosis, risk stratification
Cystatin C Prognosis, risk stratification
Plasminogen activator inhibitor
(PAI)-1
Prognosis, risk stratification
Cholesterol Prognosis, risk stratification
Urinary albumin-to-creatinine ratio Prognosis, risk stratification
Haemoglobin Prognosis
Creatinine, glomerular filtration rate Prognosis
Author's personal copy
D. Giannessi / Pharmacological Research 64 (2011) 11–24 13
in turn, early therapeutic treatments couldprogressively reduce the
incidence of this disease. For this, early diagnosis and management
of the HF patient as well as careful risk stratification are needed.
In this perspective, biochemical markers, possibly in synergy with
cardiovascular imaging markers, could help achieve this [22].
1.2. Novel biomarkers of HF and multimarker strategy
The choice of a new biomarker should be driven by the
knowledge of molecular mechanisms associated with HF, obtained
following the molecular medicine approach. Subsequently, to be
useful in clinical practice, a biomarker should fulfil the main cri-
teria of evidence-based laboratory medicine (EBLM) [23], namely
(1) to be accurately determined at a reasonable cost and with rapid
response times; (2) to provide information unavailable by clinical
evaluation; (3) to be a relevant element of the decision-making
process. It is noteworthy that appropriate statistical measures are
necessary for drawing meaningful conclusions about the clinical
usefulness of the new markers, as recently pointed out [24–27].
Many biochemical processes are known to contribute to HF
onset and progression [28,29]. In each of these pathways, the
biomarkers whose clinical use has been demonstrated, and the
emerging ones that have not yet been fully characterized, are
involved. Inflammation, neuro-hormonal modulation, myocyte
stress, oxidative stress, myocyte injury and extra-cellular matrix
remodelling are the main mechanisms associated with HF consid-
ered so far for proposal and evaluation of new biomarkers.
The complexity of the biochemical network at the basis of
HF pathophysiology clearly suggests that a single marker cannot
reflect all the features of this disease, whereas the combined use
of several indices could better characterize HF patients and create
newoptions for theirmanagement, helping identifywhich patients
to follow more closely.
The structure of this review is as follows. First, a brief survey
of the main mechanisms involved in chronic HF is given. Actu-
ally, knowledge of such molecular mechanisms is essential to the
choice of any new biomarker. Next, an extensive overview is pro-
vided as regards the results obtainedusing amultimarker approach
for HF risk stratification and to predict HF incidence in a popula-
tion as well as to evaluate the response to therapy. An insight into
transcriptomicbiomarkers, recentlyproposed forHF individual risk
assessment, is also given. Finally, advantages and limitations of the
examined studies are extensively analysed and discussed.
2. Pathophysiology of chronic heart failure
Heart failure, a final common pathway of many cardiovascular
diseases, develops when the heart is no longer able to provide ade-
quate blood flow/pressure in response to the body’s needs. This in
turn induces the activation of several compensatory mechanisms,
initially beneficial, which over time contribute to disease pro-
gression. These compensatory mechanisms include salt and water
retention by the kidneys, activation of neurohormones, and activa-
tionof intracellular signalling cascades in theheart andvasculature,
resulting in alterations of the cellular and organ morphology and
function.
In recent years, better knowledge of the role of hemodynamic
and neurohormonal factors in HF and the parallel development
of effective treatments shifted HF from an incurable to a chronic
disease [30]. For this, new research seeks increased knowledge of
the mechanisms of chronic HF in order to develop further ther-
apeutic treatments [30], targeting specific HF mechanisms. Novel
types of therapy (intracellular proteins modulation, gene delivery,
cell replacement) have been developed starting from knowledge
of the intracellular signalling pathways involved in HF molecular
mechanisms (see Refs. [1,28,30] for a more exhaustive review).
2.1. Neurohormonal activation
In response to decreased heart function, activation of the sym-
pathetic nervous system (adrenaline and noradrenaline) and of the
neurohormonal signalling (angiotensin II, endothelin and natri-
uretic peptides) is observed as a compensatory mechanism. This
activation, whose extent is correlated to heart function, increases
the rate and intensity of heart contraction, contributing to pre-
serving cardiac output. Angiotensin II signalling mediated by AT-1
receptor, sympathetic activation, and increased aldosterone pro-
duction have been reported to have a major role in cardiac
remodelling and dysfunction. Some therapies, such as blockade
of -adrenergic receptors (-AR), angiotensin-converting enzyme
(ACE) inhibitors, blockade of the angiotensin II receptor AT-1, and
inhibition of aldosterone synthesis, can improve both symptoms
and survival in HF patients [31–33]. In particular, additional effects
of AR blocker therapy have been observed, mainly related to the
kind of AR receptor subtype (1, 2, 1) targeted, e.g., 1-AR can
transactivate epidermal growth factor receptor (EGFR) signalling,
which is cardioprotective, and this mechanism is mediated by -
arrestin [34].
The pharmacological blockade of ET, whose role in pathophysi-
ology ofHF iswell demonstrated,was not effective, probably due to
the complexity of its biochemical effects, mediated by two recep-
tor subtypes with opposite actions (ET-A and ET-B). Drugs able
to inhibit only ET-A, such as the recently introduced ambrisen-
tan, might have more beneficial effects compared to less selective
receptor inhibitors, previously proposed for the clinical setting [5].
Plasma levels of ANP and BNP are increased in HF patients and
plasma BNP (or NT-proBNP) is a well-known marker of disease
severity [6]. Both ANP and BNP exert cardioprotective effects, and
infusion of BNP (nesiritide) was able to relieve symptoms when
given within 3h of the onset of worsening HF in decompensated
HF patients (see below for results of clinical trials).
2.2. Cardiac hypertrophy
Myocardial hypertrophy, a major predictor of progressive heart
disease, is a response of cardiac muscle to alterations induced
by many pathophysiological stress signals. Stress signals include
nitric oxide, neurohormones (natriuretic peptides and angiotensin
II, the latter binding to Gq/G11-protein-coupled receptors), neuro-
transmitters (catecholamines that bind to -adrenergic receptors,
-ARs), cytokines and growth factors, or cardiac injury. The early
beneficial effect of cardiac hypertrophy (normalization of wall
stress and preservation of contractile performance) may be fol-
lowed by decompensation and HF.
At the molecular level, hypertrophy is characterized by the acti-
vation of gene expression patterns of the fetal stage, such as fetal
isoformsof geneswhoseproducts regulate cardiac contractility and
calcium handling. In parallel, a down-regulation of the respective
adult isoforms is observed [35]. Impaired myocardial vasculariza-
tion, changes in the extracellular matrix composition, and fibrosis
are often associated with myocardial hypertrophy [36]. Moreover,
alterations of the normal cell turnover in the heart lead to an unfa-
vorable ratio between cardiac apoptosis and regeneration from
circulating and cardiac stem cells [37].
Fig. 1 summarizes the cardiomyocyte signalling pathways
believed to be involved in HF pathophysiology. The cardiomyocyte
signalling pathways are the same ones involved in physiological
responses, but in HF hearts there are more stress stimuli, which
amplify these molecular mechanisms and produce an imbalance
among them. The activation of cell-surface receptors by specific
ligandsorbyamechanical stimulus induces the activationof stress-
responseproteinkinasesandphosphatases, aswell asof calcineurin
which, in turn, activate transcription factors targeting multiple
Author's personal copy
14 D. Giannessi / Pharmacological Research 64 (2011) 11–24
Fig. 1. Cardiomyocyte signalling pathways involved in the pathophysiology of HF. The main intracellular signalling pathways, known to transduce the stress stimuli, are
depicted. Stress stimuli include nitric oxide, neurohormones, neurotransmitters, cytokines and growth factors. The signalling nodes (wheremanypathways converge) include
calcium (Ca2+)/calmodulin-dependent kinase II (CAMKII), Akt, glycogen synthase kinase 3 (GSK3 ) and cyclic GMP (cGMP)-dependent protein kinase (PKG). AC, adenylyl
cyclase; AKAP1, PKAanchor protein 1; cAMP, cyclic AMP;-ARs,-adrenergic receptors;DAG, diacylglycerol; FOXO, forkhead-boxOproteins;HDAC, histonedeacetylase; JAK,
Janus kinase;MAPK,mitogen-activated protein kinase;MEF2,myocyte enhancer factor 2;mRNA,messenger RNA;miRNA,microRNA;NFAT, nuclear factor of activated T cells;
NKX2-5, NK2 transcription factor related, locus 5; NO, nitric oxide; pGC, particulate guanylyl cyclase; PI(3)K-, phosphatidylinositol 3-OH-kinase-; PKA, cAMP-dependent
protein kinase; PKC, protein kinase C; PDE5, phosphodiesterase 5; PKD, protein kinase D; PLC, phospholipase C; RCAN1, regulator of calcineurin 1; ROCK, Rho-associated,
coiled-coil-containing protein kinase; sGC, soluble guanylyl cyclase; SRF, serum response factor; STAT, signal transducer and activator of transcription.
Modified from Mudd and Kass [30].
genes. The result is a change in the cellular structure, size, shape
andmolecular regulation of the heart (i.e., cardiac remodelling pro-
cess). In this process, calcineurin has a key role. Calcineurin is a
serine/threonine phosphatase able to dephosphorylate the NFAT
(nuclear factor of activated T cells) molecules, which trigger a
hypertrophic genetic program after translocation to the nucleus
[38]. Due to its crucial function in cardiac hypertrophy and remod-
elling, many therapeutic approaches have been proposed to inhibit
the calcineurin–NFAT pathway, including cyclosporin A and other
immunosuppressants used in organ transplantation.
Identification of parallel signalling cascades reduces the pos-
sibility to modulate individual signalling pathways to inhibit
pathological cardiac remodelling. However, it has been suggested
that it is possible to modulate the remodelling signals by targeting
the signalling “nodes”, e.g., pointswheremany pathways converge,
such as glycogen synthase kinase 3 (GSK3) and histone deacety-
lases (HDACs) (see Fig. 1) [30,39]. A further important therapeutic
target is represented by reactive oxygen species (ROS) because
manyof the signallingpathways reported in Fig. 1 lead to the gener-
ation of ROS that heavily contributes to decreased cardiac function
and remodelling [40].
2.3. Inflammation
Inflammatory activation is an important pathway in the pro-
gression of chronic HF. Increased plasma levels of cytokines are
found in HF patients [41,42] and TNF and other inflammatory
interleukins (IL-1, -6, -18) are produced by macrophages and car-
diac myocytes in the heart [43]. Following the cytokine hypothesis
of HF, cardiac injury induces innate stress responses, including the
production of pro-inflammatory cytokines and resulting in delete-
rious effects on cardiac function [44] and increased HF progression
[45]. Pro-inflammatory cytokines can influence myocardial func-
tion via effects on both myocyte contractility and extra-cellular
matrix, contributing tomyocardial dysfunction. In particular, TNF
affects cardiac remodelling through activation of metalloproteases
whereas IL-6 induces a hypertrophic response in myocytes [45].
For these reasons, large clinical trials aimed to evaluate the efficacy
of anti-inflammatory therapies resulted beneficial in experimental
animal models [46,47]. So far, these clinical trials have furnished
discouraging results, due to the lack of clear positive effects, or even
to a worsening of the disease [48,49].
2.3.1. TNF˛-targeting therapy
The results of TNF-targeting therapy deserve to be described in
greater detail. Several randomized placebo-controlled trials testing
anti-TNF treatments have been performed. Two trials, RENAIS-
SANCE andRECOVER, both in theRENEWALprogram, evaluated the
clinical efficacy of etanercept, a large fusion recombinant molecule
with a molecular weight of 150kDa, that binds to TNF. These
trials, as well as the ATTACH trial that tested infliximab (a mon-
oclonal antibody to TNF) did not achieve any improvement of
disease and higher rates of mortality appeared to be associated
with this therapy. A possible explanation for the lack of beneficial
effects of this therapy in HF may be the binding of the transmem-
brane form of TNF by the TNF antibody, resulting in apoptosis
of TNF-expressing cardiomyocytes [50]. It is noteworthy that
low physiological levels of TNF exert a cardioprotective role in
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the heart against acute myocardial injury, allowing tissue remod-
elling and repair [44]. Thus, the plasma levels of the anti-TNF
drugs achieved in the abovementioned trials could have reduced
the cytokine plasma concentrations below the physiological values
necessary to produce these beneficial physiological effects. More-
over, during anti-TNF therapy, high levels of the drug could be
obtained with consequent dose-dependent toxicity [49]. Finally,
the selectionof patients to test is a crucial issue. Among thepatients
with HF, elevated circulating levels of TNF have been generally
found in those with more severe disease (NYHA functional class
IV) while only 3% in the RENEWAL and 5% of the population in
ATTACH were in NYHA class IV, a population too small to obtain
reliable data on therapy efficacy. These observations suggest that
for evaluation of the efficacy of anti-TNF therapy, it is necessary to
carefully test the optimal pharmacological preparation and dosage
in specific patient sub-groups, as indicated by “A Consensus State-
ment of the Heart Failure Association of the European Society of
Cardiology” on this topic [51]. Indeed, inflammatory activationmay
be different in the different phases of HF (e.g., early stage HF after
acute myocardial infarction compared with chronic HF) or in the
different forms of HF (ischemic, diabetic, hypertensive, viral, and
idiopathic cardiomyopathy). The results of anti-inflammatory trials
gave rise to many relevant questions about the role of inflamma-
tion in HF pathogenesis and the clinical use of anti-inflammatory
therapies. The Consensus Statement [51] highlighted some other
critical issues in addition to the abovementioned careful selection
of patients. The Consensus Statement strongly indicates that pre-
clinical data in animal experimental models must be obtained in
the same conditions as the patients enrolled for anti-inflammatory
therapies: indeed, animal models often use relatively acute mod-
els whereas clinical trials evaluate chronic HF patients [51]. Finally,
novel therapeutic targets to inhibit inflammation in the heart have
been proposed, including pentraxin (PTX)3 and matricellular pro-
teins (seeTable1). Regardinganti-TNF therapy, approaches aimed
at blocking its synthesis or release should also be considered [51].
2.4. Apoptosis
In the failing heart, an imbalance between signalling path-
ways that promote cell survival and those that promote cell death
(apoptosis and necrosis) leads to a decrease in the number of car-
diomyocytes. The programmed cell death could be triggered in
cardiac myocytes by various kinds of stressors, such as cytokines,
free radicals, hypoxia and DNA damage. The sustained loss of car-
diomyocytes by apoptosis has a critical and important role in
pathogenetic progression of cardiomyopathies [52], and in this
context the proapoptotic factors could contribute to contractile
dysfunction by reducing the myofibrillar turnover into the car-
diomyocytes [53,54]. Initiation of apoptosis is associated with
activation of the upstream cascade, including the inhibition of Akt
phosphorylation [55], the release of Cytochrome C from mitochon-
dria to cytoplasm and the processing of proteolytic caspases (Casp)
[56]. Casp expression and activation represents the end-stage of
apoptotic signalling, even leading to fragmentation of various cyto-
plasmic proteins, including contractile proteins [53,57]. Recently, it
has been postulated that apoptosismight be one of themeta-stable
transition states in HF, which may be reversible with appropriate
therapy [54]. Indeed, treatment able to reverse apoptosis could
help restore systolic function and reverse remodelling, attenuat-
ing the severity of HF [58,59]. It is conceivable that the activation
of apoptosis is not homogeneous in the myocardium and does
not immediately affect contractile function. In fact, it has been
established that not all cardiac cells succumb to apoptotic acti-
vation and surviving cells might drive mechanisms to interrupt
the process of apoptosis, despite Casp activation or Cytochrome C
release [56,60]. The mechanism by which apoptosis is interrupted
is still under investigation. Previous data suggest that interrup-
tion of the apoptotic process might be due to an adaptive balance
between pro- and anti-apoptotic soluble factors to limit cell stress
and dysfunction. The presence of this balance has been demon-
strated in the cardiac tissue from an animal experimental model
of pacing-induced HF [61]. The findings of this study indicate that
the apoptotic process is activated in failing hearts, as shown by
the significantly increased expression of Casp-3, but this activa-
tion is not accompanied by an increase in apoptotic cells or DNA
fragmentation. This observation closely agrees with the contem-
poraneous activation of the apoptosis control systems in HF, B-cell
lymphoma 2 (Bcl-2) and heat-shock protein (HSP)72, both over-
expressed in HF hearts. It has been hypothesized that cells try to
resist apoptotic stimuli over-expressing anti-apoptotic molecules,
such as Bcl-2, in order to prevent the complete activation of the
cellular death program.
More attention is devoted to promoting cardiac regeneration in
failing hearts and many studies used infarcted hearts to attempt
to restore cardiomyocytes near the scar. Although it is more dif-
ficult to use this strategy with a heart with a global dysfunction,
recent data suggest that the efficacy of cell-based therapy may be
due to paracrine effects of injected cells on endogenous cells [62],
thus indicating the induction of such paracrine effects as a novel
therapeutic target.
2.5. Myocardial metabolism
Cardiac energy supply andmetabolism are tightly regulated, the
heart having a higher and constant workload. A deregulation of the
energetic metabolism, as found in HF, results in a state of ineffi-
ciency and energy starvation. Due to the low capacity of the heart
for storing the substrates, these have to be produced efficiently
and rapidly, mainly from free fatty acids and, to a lesser extent,
fromglucose. InHF the synthesis of adenosine triphosphate (ATP) is
reduceddue tomitochondrial dysfunctionandpossible altered sub-
strate utilization (increased catabolism of glucose). Fig. 2a shows
the differences in metabolism and energy regulation between nor-
mal and failing hearts. In the normal heart, oxidation of fatty acid
is preferred to glucose oxidation whereas in the failing heart there
is an increased glucose oxidation associated with a reduction in
production of the transcriptional coactivator PGC1 (peroxisome-
proliferator-activated receptor- (PPAR-) coactivator 1). PGC1
regulates the expression of the transcription factors PPAR-, ERR-
 (estrogen-related receptor-), NRF1 (nuclear respiratory factor
1), and NFR2 that regulate mitochondrial biogenesis and fatty acid
oxidation. Another relevant concern in the dysregulation of energy
metabolism in HF is the abnormal storage of ATP in this condi-
tion. When it needs to produce energy rapidly, ATP is obtained
from phosphocreatine and adenosine diphosphate (ADP) by the
reversible action of creatine kinase (Fig. 2b); thus phosphocrea-
tine represents a reserve of ATP. The ratio of phosphocreatine and
ATP is considered a measure of this energy balance; this ratio is
altered in the failing heart, due to the reduced activity of the cre-
atine kinase, with consequent abnormalities in ATP availability
[63]. Another important feature influencing energy availability is
the density of capillaries in cardiac muscle. In an animal model
of hypertrophy, cardiac remodelling resulted associated with an
angiogenetic process unable to respond to the muscle growth [64].
The balance between hypertrophy (muscle growth) and capillary
density (nutrient supply) is partly regulated by the transcription
factor GATA 4, which has an important role in the stimulation of
angiogenesis [65]. Thus, modulation of the balance between pro-
and anti-angiogenetic factors could be relevant as a novel thera-
peutic target in some clinical conditions [30].
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Fig. 2. Metabolism and energy regulation in healthy and failing hearts. (a) Different
oxidation patterns and transcription cascades between healthy conditions (left) and
HF (right). (b) ATP generation from phosphocreatine and ADP.
Modified from Mudd and Kass [30].
2.6. Contractile machinery
Themechanical function of the heart is associatedwith the force
generated by the sarcomere, through the interaction of myosin
thick filaments with actin thin filaments. Two isoforms of myosin
heavy chain ( and ) are expressed in the heart and their rela-
tive proportions are affected by many pathophysiological stimuli.
Normal heart of adult rodents contains -myosin heavy chain that
differs from fetal -myosin heavy chain for faster cross-bridge
kinetics and less tension generated. In HF, the gene encoding for
fetal -myosin heavy chain is re-expressed and represents about
50% of the total myosin heavy chain. In the human heart,-myosin
heavy chain is prevalent in healthy conditions and in failing hearts
a further reduction of -myosin heavy chain is observed [66].
This observation suggests that treatments aimed at increasing the
expressionof-myosinheavy chain couldproveuseful.Manyother
proteins are found in the sarcomere: troponins and-tropomyosin
(regulatory thinfilaments),myosin-bindingprotein C and titin, also
known as connectin (interlinking proteins) and the Z-disc proteins
(-actinin, vinculin, and talin). The Z-disc functions as a physical
anchor for myofilament and cytoskeletal proteins and as a coordi-
nation center for the reception and transduction of mechanical and
biochemical stress signals. Alterations in the proteins of the Z-disc,
affecting both the integrity of the Z-disc and the intracellular sig-
nalling, induce dilated cardiomyopathy in humans and in animal
models [28,30].
Sarcomere proteins, being the connection between mechanical
forces and protein kinase and phosphatase signalling, could repre-
sent new targets for modulating contractile function [30].
Myofibrillar proteins, the cardiac TnI and T, sensitive and spe-
cific marker of myocyte injury in patients with acute coronary
syndromes, resulted slightly increased in HF patients, but associ-
ated with poor prognosis [17,18]. Other myocyte proteins, namely
H-FABP, myosin light chain 1 (see Table 1), are found in the periph-
eral circulation of HF patients, and their presence, as well as for
troponins, reliably predicts the outcome in HF patients [19,67].
3. Multimarker strategy for HF management
In this section, the main results regarding the multimarker
approach toHF are reviewed. A summary of themain studies exam-
ined in this section can be found in Table 2.
3.1. Risk stratification of HF patients
Assessment of cardiovascular risk is an integral part of clinical
decision-making, especially for the rational use of pharmacologi-
cal therapies or/and device-based procedures. Critical evaluation
of new risk markers has become even more relevant, and should
be based on a sound study design and a representative population.
Because HF is a major public health problem and the severity of
disease must be graded, many clinical studies have been devoted
to finding suitable markers to improve risk stratification in fail-
ing patients. Rates of hospitalization increase steadily both in the
Europe [68] and in the United States [69], mortality following hos-
pital discharge reaches one-third of patients within the first year
post-hospitalization and about 70% within 5 years of admission
[70,71]. New therapeutic treatments have been developed and
someof themarequite expensive; thus it is urgent to easily, reliably
and cost-effectively stratify severely ill HF patients so the patients
at the highest risk will receive the most intensive care.
Among the many biomarkers that have been checked for risk
stratification, BNP, an index of cardiac failure and volume over-
load, is the most well-established and frequently used in all studies
that apply a multimarker approach. Although minor myocardial
injury seems to be associated with HF, specific markers of cardiac
necrosis, suchas cTnandH-FABP, areoften selected in the combina-
tion. Inflammation, due to its fundamental role in pathophysiology
and prognosis of HF, is also considered by adding the evaluation of
CRP to the multimarker panel, or, more recently, of PTX-3. Other
molecules have also been considered to highlight a possible fail-
ure of other systems involved in HF pathophysiology. Two studies
involving cystatin C, an index of kidney function [72], and free tri-
iodothyronine (T3) [73], respectively, are reported below, as well
as a study using a combination of conventionalmarkers beside BNP
[74].
The studies described below furnish an overview of the per-
formance of different multimarker combinations employed for HF
patient risk stratification. They may help for the critical appraisal
of risk assessment strategies to be used clinically.
In the prospective study of Ishino et al. [14], 164 consecutive
patients admitted to the cardiacunit for the treatmentofworsening
HF (NYHA classes I–IV; LVEF 49.6±19.3%)were enrolled. Themean
follow-up was 679±438 days and the end-points were cardiac
death and readmission for worsening HF. The chosen biomarkers,
BNP,H-FABPandPTX-3,weremeasuredat admission. Patientswith
all three markers higher than the respective cut-off (score 3) pre-
sented the highest risk with respect to the other groups with a
lesser number of elevated biomarkers (34.6-foldwith respect to the
score 0) (Fig. 3). A similar indicationwas obtained by Kaplan–Meier
analysis that demonstrated that cardiac events occurred most fre-
quently in patients with three elevated biomarkers. These findings
showed that the combination of BNP, H-FABP and PTX-3, reflecting
different aspects of the disease, is a highly reliable method for risk
stratification of hospitalized failing patients.
Similar results were obtained by a community cohort study,
in which BNP, CRP, and cTnT levels were determined in 593 HF
patients (NYHA classes III–IV) with preserved ejection fraction
(LVEF: 48.7±16.4%) [26]. Higher levels of all three biomarkers
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Table 2
Multimarker combinations for HF management.
Reference Biomarkers Aim Study population HF medication
Ishino et al. [14] BNP+H-FABP+PTX3 Risk stratification NYHA classes I–IV ACEIs/ARBs 64%
-Blockers 37%
CCBs 20%
Diuretics 71%
Statins 18%
Dunlay et al. [26] BNP+ cTnT+CRP Risk stratification Community (Olmsted
County, MN, US) NYHA
classes III–IV (71%)
ACEIs/ARBs 58.5%
-Blockers 65.1%
Statins 50.9%
Zairis et al. [75] BNP+ cTnT+CRP Risk stratification Decompensated HF
NYHA classes III–IV
ACEIs/ARBs 84.1%
-Blockers 60.7%
Spironolactone 29.8%
Manzano-Fernández et al. [72] Nt-proBNP+ cTnT+ cystatin C Risk stratification Acute HF
NYHA classes III–IV
(30%)
ACEIs/ARBs 80%
-Blockers 51%
Statins 49%
Spironolactone 32.4%
Loop diuretics 84.1%
Passino et al. [73] BNP+ fT3 Risk stratification NYHA classes I–IV ACEIs/ARBs 91%
-Blockers 78%
Diuretics 77%
Niizeki et al. [74] BNP+ conventional biomarkers Risk stratification NYHA classes III–IV ACEIs/ARBs 70%
-Blockers 31%
CCBs 17%
Spironolactone 33%
Loop diuretics 77%
Statins 11%, digoxin
36%
Velagaleti et al. [86] BNP+PCR+PAI-
1 +homocysteine + aldosterone-
to-renin ratio +urinary
albumin-to-creatinine ratio
Incidence prediction Community
(Framingham offspring
study participants)
Frankel et al. [89] adiponectin + resistin Incidence prediction Community
(Framingham offspring
study participants)
Miller et al. [94] BNP+Nt-proBNP+MR-
proANP+ copeptin +
procalcitonin +neopterin
Therapy response Decompensated HF
NYHA classes III–IV
ACEIs/ARBs 70%
-Blockers 70%
Diuretics 85%
Aspirin 70%
Digoxin 53%
Nitrates 30%
Hydralazine 10%
Heidecker and Hare [106] Molecular biomarkers
(endomyocardial biopsy)
Risk stratification New-onset HF
NYHA classes I–IV
ACEIs 67%
-Blockers 26%
Diuretics 75%
Aldosterone antagonist
19%
Lamirault et al. [108] Molecular biomarkers
(endomyocardial biopsy)
Risk stratification Advanced HF ACEIs/ARBs 84%a
-Blockers 70%
Aldosterone blockers
53%
Statins 32%
Digoxin 26%
Adrenergic agonists
42%
BNP: B-type natriuretic peptide; H-FABP: heart-type fatty acid binding protein; PTX3 pentraxin-3; cTnT: cardiac troponin T; fT3: free triiodothyronine; MR-proANP:
midregional pro-atrial natriuretic peptide; PCR: C-reactive protein; PAI-1: plasminogen activator inhibitor-1; CCBs: calcium-channel blockers.
a Percent values refer to patients of the intermediate HF-severity group.
proved to be strong, independent predictors of mortality and each
biomarker provided incremental prognostic value with respect
to classic risk factors. An improved 1-year risk prediction was
obtained by adding a two-biomarker combination (BNP and CRP)
to a model including established risk indicators (age, BMI, NYHA
class, creatinine clearance, systolic blood pressure) (integrated dis-
crimination improvement gain of 7.1%, p<0.001). The addition of a
third biomarker did not contribute further benefits.
A combination of BNP, CRP, and cTnT was also prospectively
investigated in the setting of acutely decompensated low-output
HF patients (NYHA classes III–IV; LVEF: 22.7±5.4%; LVEF ≤25 in
58.6% of patients) for early risk stratification [75]. Biomarkers were
measured at admission in a total of 577 subjects, recruited at five
different Greek centers. The relative risk of 31-day cardiac mor-
tality, which was the study endpoint, increased as a function of
the number of elevated biomarkers (4.3%, 10%, 20.9% and 53.5% of
patients with 0, 1, 2, 3 elevated biomarkers, respectively, reached
the study endpoint). Fig. 4 presents the relative risk of 31-day car-
diac mortality as a function of the number of the elevated study
biomarkers. These findings confirm the robustness of the combina-
tion of a marker of myocyte stress with a marker of myocyte injury,
and an inflammation marker.
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Fig. 3. Cardiac mortality and all cardiac events as a function of biomarker score.
Patients with score 3 had significantly higher rates of rehospitalization and car-
diac death than those with score 0–2 (p<0.0001 by chi-square test). Cut-off values
(200pg/mL for BNP, 4.1ng/mL for H-FABP, and 4.0ng/mL for PTX3, respectively)
were determined by ROC curves.
Modified from Ishino et al. [14].
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Fig. 4. Bar chart representing the relative risk of 31-day cardiac mortality as a
function of the number of the elevated biomarkers.
Modified from Zairis et al. [75].
The study by Manzano-Fernández et al. [72] added the deter-
mination of cystatin C, for evaluation of kidney function, to the
measurement of NT-pro-BNP and cTnT, whose combination was
shown to improve the risk stratification in HF patients [76,77].
A total of 138 patients, admitted with initial diagnoses of acute
HF (LVEF: 30–65%), were prospectively studied and the median
follow-up was 261 days. Elevated levels of cystatin C resulted
in a significant independent risk factor for adverse events (the
combination of death and/or HF readmission). Moreover, the mul-
timarker approach improved risk stratification further, showing
that patients with 2 or 3 elevated biomarkers had a higher risk
for adverse events than patients with no elevated biomarkers
(25.8%, 37.1%, 43.6% and 66.7% of patients with 0, 1, 2, 3 elevated
biomarkers, respectively, reached the study endpoint). The asso-
ciation between higher levels of cystatin C and increased rate of
adverse clinical events, found in this work, strongly indicates that
the evaluation of kidney function should have a pivotal role in the
risk stratification of these patients in whom an impaired kidney
function is related to worse outcomes [78].
The study by Passino et al. [73] is based on the observation that
alterations of thyroid function are present in HF patients without
primary thyroid disease [79,80]. About 30% of HF patients have low
levels of the biologically active T3 and normal values of TSH and T4.
This “low-T3 syndrome” is associated with a poor outcome [79],
but its negative prognostic power is enhanced in those patients
with higher BNP, as shown in Fig. 5, where survival curves as a
function of BNP and free T3 values are reported. Data refer to a
total of 720 consecutive HF patients of different severities (NYHA
classes I–IV; LVEF: 33.5±9.9%) followed-up for 7 years (median
value 3 years). The additive prognostic power of BNP and free T3
was demonstrated by the analysis of the survival curve of those
patients with high BNP and low free T3, who showed the highest
mortality rate. On the contrary, patients with combined low BNP
and normal free T3 showed the lowest rate. Moreover, low free T3
was able to identify patients with higher risk of death among those
with relatively low BNP.
Many mechanisms have been suggested to explain how free T3,
which is not a cardiospecific biomarker, is involved in the prognosis
of HF. T3 is mainly produced by 5′ monodeiodination of thyroxine
(T4) in liver and free T3 can be considered an index of dysfunc-
tion of peripheral tissues, including liver, kidney, andmuscles, thus
low free T3 serum levels might reflect a condition of advanced dis-
ease (pre-cachectic stage). Moreover, low free T3 has important
hemodynamic effects on cardiovascular function associated to the
reduction of positive inotropic and vasodilatory effects of T3 and of
its trophic action on the heart [81,82]. Although the link between
low T3 and HF progression is not completely understood, a proof of
its pathophysiological role is the restoration of the neuroendocrine
condition observed after administration of synthetic T3 in patients
with HF [83].
At a time of increasing interest in the proposal and use of
newer biomarkers for identification, risk assessment and care of
HF patients, as the authors themselves underlined, Niizeki et al.
[74] have evaluated the incremental usefulness ofmultiple conven-
tional biomarkers for risk stratification. They chose a combination
of seven biomarkers, each assessing different pathophysiologi-
cal mechanisms and known to be independently associated with
increased risk of cardiac events in HF patients. BNP, uric acid,
Fig. 5. Kaplan–Meier survival curves for all-cause (left) and cardiac (right) mortality in 4 sub-groups identified according to cut-off values: 2.1ng/L for fT3, and 165ng/L for
BNP (168ng/L for cardiac mortality).
Modified from Passino et al. [73].
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Fig. 6. Kaplan–Meier analysis in HF patients stratified into 3 groups based on multimarker score (top). Cardiac mortality and cardiac events among the 3 groups (bottom).
Patients were categorized into 3 groups according to the multimarker score: low stratum (multimarker score 0–3), intermediate stratum (multimarker score 4), high stratum
(multimarker score 5–7). Patients of “high” group had significantly higher rates of total cardiac events and cardiac deaths compared with “lower” group.
Modified from Niizeki et al. [74].
high sensitive-CRP, sodium, haemoglobin, creatinine, and creati-
nine clearance were measured at admission in 154 patients (NYHA
classes III–IV, LVEF: 42±19%). Patients were divided in three
groups following a multimarker score calculated considering the
cut-off values of each biomarker. The patients were prospectively
followed (mean follow-up 526±313 days), end-points being car-
diac death and readmission for worsening HF. Fig. 6 shows that
the percentage of total cardiac events increases as a function of
the score value in close agreement with the Kaplan–Meier analy-
sis, thus showing that this simple multimarker approach has the
potential to assist clinicians in predicting prognosis in HF patients,
with low cost and wide availability.
3.2. Prediction of HF incidence
Refining HF risk prediction is a fundamental step in targeting
prevention strategies. A HF “risk profile” based on clinical, ECG,
and radiological features was described by the investigators of the
FraminghamHeart Study [84]. These clinical factors, though, do not
fully explain the HF risk [85]. For this, many circulating and urinary
substances have been proposed to describe the several biochemical
pathways involved in the HF evolution; however, at present there
are no data on the incremental utility of “a parsimonious set of
biomarkers” for predictingHF risk in the community [86]. To obtain
reliable indications about the factors involved in the disease onset,
longitudinal community based studies are essential. Indeed, the
main information about the prediction of HF incidence is derived
from the Framingham Offspring study, a longitudinal community-
based study initiated in 1971. A sample of 5135 individuals who
were children (or spouses of children) of the original Framingham
cohort study,were enrolled in the FraminghamOffspring study and
examined approximately every 4 years (the next exam is scheduled
tobegin in2011). Theobjectiveof the studywas to identify common
factors or characteristics that contribute to cardiovascular disease
by following its incidence, over a long period of time, in a large
group of participants who had not yet developed overt symptoms
of cardiovascular disease or suffered a heart attack or stroke [87].
In this context, very recently, a multimarker panel was related to
the incidence of a first HF event in a prospective investigation of
a large community-based sample of middle-aged whites (n=2754
from the participants to the Framingham Offspring study, at the
sixthexaminationcycle) [86]. A combinationof sixbiomarkers, pre-
viously checked as indices of LV remodelling and vascular stiffness
[29,88], was used, including CRP, plasminogen activator inhibitor-
1, homocysteine, aldosterone-to-renin ratio, BNP and the urinary
albumin-to-creatinine ratio. Among these indices, BNP and the uri-
nary albumin-to-creatinine ratio were key biomarkers associated
with HF risk. The predictive power of these two indices underlines
the importance of natriuretic peptide activation and endothelial
dysfunction as marker of disease. However, as declared by the
authors themselves, the incremental usefulness of these biomark-
ers over standard clinical factors is very modest and additional
studies are required to assess the applicability of these indices to
routine clinical setting.
Although it is not a “true” multimarker approach, it is worth
quoting the paper of Frankel et al. [89] where the circulating
concentrations of adipokines, resistin [90] and adiponectin [91,92]
are associated with the incidence of HF because the results of its
study strongly suggest the existence of new molecular pathways
leading to HF. A total of 2739 participants in the Framingham
Offspring study were followed up for 6 years. The study hypothesis
was that greater concentrations of resistin and lower concen-
trations of adiponectin would be associated with an increased
risk of HF. Increased peripheral levels of resistin were associated
with incident HF, even after accounting for obesity, inflammation,
insulin resistance, and concurrent coronary heart disease, whereas
adiponectin was not associated with subsequent development of
HF. Although the specific mechanisms whereby resistin, known to
promote insulin resistance and inflammation, leads to HF are not
fully elucidated, the results of this study underline the importance
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Fig. 7. Bar chart illustrating the pathways involved within the prognostic biomarker. Major pathways overexpressed in patients with good prognosis included transcription
(26%), protein binding (15%), ion transport (13%), and neuro-muscular development (10%).
Modified from Heidecker and Hare [106].
of evaluating new biochemical patterns associated with onset
of HF.
3.3. Monitoring the response to therapy
Evaluation of the response to therapy in HF patients is a crucial
issue, especially in themore vulnerable patients to be followedvery
carefully, such as patientswith decompensatedHF. Althoughmany
studies evaluated the response to therapy, mainly using neurohor-
mone levels [93], a “true”multimarker platformhas been only used
to check the response to nesiritide infusion in decompensated HF
patients [94].
3.3.1. Monitoring of recombinant human BNP infusion
Nesiritide, a recombinant form of human BNP approved in 2001
to treat decompensated HF, was proposed as a novel and poten-
tially important advance in the care of these patients [95]. This
drug might be able to relieve dyspnea when given within 3h of the
onset of worsening HF, but possible harmful side effects, including
renal impairment or increased risk of death, have been indicated.
The Acute Study of Clinical Effectiveness of Nesiritide in Decom-
pensated Heart failure (ASCEND-HF), a multicenter double-blind
randomized trial, which enrolled 7141 patients to receive either
intravenous nesiritide or placebo in addition to standard therapy,
aimed to evaluate whether this drug is able to improve symptoms
and influence the outcome in acute, severe HF [96]. The results
of ASCEND-HF indicated that recombinant human BNP is safe in
patientswith severeHF, but is not associatedwith significant symp-
tomatic relief or improved outcome [96,97]. As to the biohumoral
evaluation of the effects of nesiritide, a multimarker paradigm was
proposed for monitoring the response to drug infusion in decom-
pensated HF patients [94] because the BNP and NT-proBNP were
not fully able tomonitoring the response to thedrug. The changes in
BNP andNT-proBNP levels after therapywere not rapid nor as large
as expected from the clinical response, and further markers would
benecessary toevaluate thedrugeffect [94]. Fournovelbiomarkers,
copeptin, midregional proatrial natriuretic peptide (MR-proANP),
neopterin, and procalcitonin, in addition to BNP and NT-proBNP,
were checked in a prospective study of 40 patients hospitalized
for decompensated HF (LVEF: 25±1.4%) -and treated with BNP as
a part of their care. The combination included two inflammatory
biomarkers: procalcitonin, a precursor of calcitonin and a marker
of systemic infection and inflammation [98], and neopterin, a small
peptide produced by macrophages [99]. Circulating levels of the
selected biomarkers were elevated in patients with HF and appear
to have prognostic value [100].
Before niseritide infusion all biomarkers were higher than
normal range, but copeptin, MR-proANP, and NT-proBNP levels
significantly decreased in response to the therapy. Copeptin and
MR-proANPresultedpotentially associatedwith theacute response
to therapy, while higher copeptin levels indicated the non-survivor
patients after discharge and were associated with an increased
mortality risk. The addition in the statistical analysis of neopterin
and procalcitonin did not result in incremental information in
response to therapy and risk stratification. Only copeptin and BNP
contributed to risk stratification in this group of severe HF patients,
althoughBNPorNT-proBNPdoesnot influence theprognostic value
of copeptin alone.
This study highlights the role of copeptin (C-terminal vaso-
pressin) in HF pathophysiology. Copeptin is synthesized and
secreted in equimolar amounts to vasopressin, an anti-diuretic and
vasoconstricting hormone strongly related to the severity and out-
come of HF [101]. Instead of vasopressin, copeptin is highly stable
and can be easily and reliably measured in unprocessed plasma or
serum; its predictive value resulted superior to benchmark mark-
ers, BNP and NT-proBNP, over the entire spectrum of HF in a study
of Neuhold of 2008 [102] as well as in patients with HF after acute
myocardial infarct (OPTIMAAL study) [103].
3.4. Molecular biomarkers for individual risk assessment
New indications relative to management of failing patients
would derive from basic research, in particular from genetic stud-
ies. One of the most valuable applications of genomic information
has proven to be clinical prediction [104]. Indeed, the pattern of
differentially expressed genes, besides providing insight into dis-
ease origin, has been also successfully used for the development
of biomarkers, such as in neoplastic disease [105]. This approach,
now emerging in many other diseases, has been addressed to the
possibility of accurately assessing the prognosis in patientswithHF
[106,107], a major unmet issue in the management of HF. In this
context,microarrayanalysis of cardiacbiopsies allowsus to identify
a transcriptomic biomarker profile able to improve the individual
risk assessment and potentially to offer novel therapeutic targets
[107]. Using this technique, a transcriptomic signature, generated
from a single endomyocardial biopsy, resulted in a novel prognos-
tic biomarker in HF in subjectswith new-onset HF (LVEF: 24±13%)
[107].
A total of 43 bioptic samples, chosen from among a total of
350 endomyocardial biopsy samples collected for evaluation of
cardiomyopathy from1997 and 2006,were analysed. To avoid pos-
sible disease-specific confounding factors, only samples of patients
with idiopathic dilated cardiomyopathywere selected. Biopsy sam-
ples were further selected in a case–control fashion, based on the
phenotypic extremes in survival of the cohort: a group with good
prognosis (n=25) was defined as having event-free survival for at
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least 5 years after initial presentation with HF symptoms; a group
with poor prognosis (n=18) had an event (death, requirement for
ventricular assisted device, and cardiac transplant) within the first
2 years of HF onset. The patient group with good prognosis pre-
sented 46 over-expressed genes with respect to patients with poor
prognosis. Molecular mechanisms with major involvement were
transcription (26%), protein binding (15%), ion transport mecha-
nisms (13%), and neuro-muscular development (10%), as can be
seen in Fig. 7, which illustrates the pathways involved within the
prognostic biomarker.
More recently, a cardiac gene expression profile has been pro-
posed for risk stratification in advanced HF, a crucial issue for the
following therapeutic treatments, e.g., heart transplantation and
LVAD implantation [108]. Cardiac tissue samples from left (LV)
and right (RV) ventricles of 44 patients undergoing heart trans-
plantation or LVAD implantation were checked by a microarray
containing 4217 muscular organ-relevant genes. Two gene expres-
sion profiles, for LV and RV respectively, were identified, both able
to discriminate deteriorating from stable patients with high sensi-
tivity (>88%) and specificity (>96%).
4. Discussion
Most of the multimarker approaches for HF patient manage-
ment address a major question in HF care, which is the accurate
clinical prediction of patient prognosis. It is well-known that
patients with very similar conditions at disease onset and under-
going similar therapies, can have very different outcomes: a few
patients are able to recover heart function in the subsequent 5
years, whereas in others the disease rapidly progresses and aggres-
sive interventions arenecessary. Thepossibility of identifying these
more severe patients is clinically important, especially considering
thatmany therapeutic interventions, includingmechanical circula-
tory assistance or cardiac transplantation, are available today. This
goal has not been achieved yet although many novel biomarkers
[86] as well as clinical prediction algorithms [26] have been pro-
posedandchecked.Manybiologicalmarkers, reasonablyassociated
with HF pathophysiology, have been considered and their num-
ber increases with the increase of knowledge regarding molecular
mechanisms of HF. The multimarker approach, considering simul-
taneously various biochemical pathways, bases its robustness on
a suitable choice of indices known to be individually associated
with HF. The combination of the biomarkers is the clue for the per-
formance of the multimarker strategy and it generally reflects the
mainprocesses ofHF. It always includes BNP (orNT-proBNP), a con-
solidated marker of dysfunction; then other markers, associated
with pathways known to be modified in HF, such as inflammation,
cardiac injury, renal failure, thyroid function, andmetabolism,were
added in the combination. However, the increase in the number
of biomarkers included in the panel aimed at evaluating as many
molecular processes as possible is limited by the observation that
the addition of further markers in a combination often does not
improve its diagnostic/prognostic power [26]. Moreover, although
the combineduseofmanybiomarkersbetterdescribes thepatient’s
condition, none of the proposed multimarker strategies resulted
univocally able to accurately assess patient prognosis [86].
The limited accuracy and increasing healthcare cost of the mul-
timarker platform suggest the need to develop new tools for HF
risk stratification,management, and therapy control. The relevance
of gene expression and molecular signature analysis for potential
clinical applications of transcriptomics is increasing. Recent tech-
nological advances in genomic screening and robust technologies
arenowavailable for entire genomescreening for expressionor sin-
gle nucleotide polymorphisms. Recently, cardiac gene expression
profiles obtained by an endomyocardial biopsy suggest the poten-
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Fig. 8. Health outcome (yield) as a function of the cost. For any new intervention it
will need to evaluatewhere it falls on the curve of additional yield in terms of health
benefit versus additional cost.
Modified from Cowie [110].
tial of transcriptomic biomarkers to predict prognosis in patients
with HF [107,108]. This exciting technique presents some limi-
tations: firstly, the time of bioptic sampling is critical owing to
possible compensatory transcriptomic changes that could have
been activated during disease progression [109]; second, although
the endomyocardial biopsy is a low-risk procedure it is not easy to
transfer to the clinical routine, andmethods forobtaining transcrip-
tomic biomarkers, alternative to biopsy, must be proposed. For this
purpose, circulating blood cells, often sharing common genes with
target tissues, would be the sample of choice for clinical applica-
tions. Many studies will need to assess whether the information
obtained by biopsy analysis is completely reproduced by tran-
scriptomic analysis of peripheral cells or if a combination of tissue
and circulating biomarkers could increase the prediction accuracy.
Finally, the combination of transcriptomic biomarkers and classic
established biomarkers must be evaluated.
As to the use of biomarker panels for refining HF prediction, a
fundamental phase for preventing the disease, large sample size,
standardized measurements of biomarkers and a rigorous defini-
tion of HF events are necessary.
A major problem in the choice of the biomarker profile is the
proportionally increased economic burden; thus a “parsimonious”
biomarker combination should be used in a cost-effectiveness
evaluation. The key question for this as well as for all other
new interventions is to evaluate whether the new intervention
improves outcome sufficiently to justify the additional cost [110].
This is depicted in Fig. 8, reporting the relationship between the
additional yield in termsof clinical outcomeand the additional cost.
Finally, it is noteworthy that a common limitation of all the multi-
marker panels, besides the need for suitable and robust statistical
analysis, is thatdifferences in theanalytical performance, especially
precision, of the assays of the different markers may influence the
results of the analysis.
The final aim of the application of multimarker strategies to a
clinical setting is to improve patient prognosis by better describing
its conditions and, in turn, by better addressing its care. The robust-
ness of this sequence has been confirmed by the data, recently
published, of a population-based study relative to hospitalizations
inScotland from1997 to2003 [111]where theobserveddecrease in
the rates of first hospitalization for HF resulted associated with the
increase in prescribing rates of evidence-based pharmacological
treatments, such as ACE inhibitors, spironolactone and -blockers.
5. Conclusions
The approach to an accurate individualization of HF incidence
risk and carewould benefit fromaprofile of laboratory data, includ-
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ing gene expression analysis, in addition to clinical data. However,
many intrinsic limitations are associated with the multimarker
approaches proposed for evaluation of HF incidence and HF man-
agement. The increased information provided by the simultaneous
evaluation of different aspects of HF syndrome does not suffice to
cover all the mechanisms involved in or influencing HF onset and
progression, due to the correspondingly increased economic and
organizational burden. Statistical analysis and analytical perfor-
mance of the different elements of the combination may in turn
greatly influence the results. Although fully automated platforms
that are able to reliably measure biochemical and transcriptomic
indices may soon reduce the economic and technical problems,
evaluation of the incremental usefulness of this type of approach
remains the central issue, and must be clearly assessed in routine
clinical settings.
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